A Practical Immunohistochemistry-Based Model for Predicting Pathologic Complete Response in Estrogen Receptor-Strong Positive and HER2-Negative Breast Cancer Running title: IHC-Based Prediction Model of pCR in ER-Positive HER2-Negative Breast Cancer
IHC-based model predicts pCR in ER-positive HER2-negative breast cancer, suggesting personalized treatment choices.
Key Points
To develop a model that predicts pathologic complete response (pCR) in patients with ER-positive and HER2-negative breast cancer receiving neoadjuvant chemotherapy (NAC).
Developed an IHC-based prediction model.
Identified patient subgroups based on immunohistochemistry scores.
Evaluated correlations between pCR and survival benefits.
Patients with high IHC scores showed improved pCR rates following NAC.
Low- or intermediate-scorers may benefit more from surgery and endocrine therapy than NAC.
Model assists in personalizing treatment strategies for patients.